Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8326 to 8340 of 9079 results

  1. Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]

    Discontinued Reference number: GID-TA11265

    Technology appraisal guidance
    Discontinued

  2. Etripamil for treating paroxysmal supraventricular tachycardia [ID6581]

    In development Reference number: GID-TA11750 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. VTS-270 for treating Niemann-Pick type C1 [ID1267]

    Discontinued Reference number: GID-HST10020

    Highly specialised technologies guidance
    Discontinued

  4. Arimoclomol for treating Niemann-Pick disease Type C [ID1312]

    In development Reference number: GID-HST10037 Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  5. Venglustat for treating gangliosidoses in people 2 years and over [ID6358]

    Discontinued Reference number: GID-TA11396

    Technology appraisal guidance
    Discontinued

  6. Mavacamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6523]

    In development Reference number: GID-TA11664 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]

    In development Reference number: GID-TAG499 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223

    Discontinued Reference number: GID-HST10019

    Highly specialised technologies guidance
    Discontinued

  9. Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over [TSID11847]

    In development Reference number: GID-TA11372 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Insulin efsitora alfa for treating type 1 diabetes in people on multiple daily insulin injections [ID6498]

    In development Reference number: GID-TA11645 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Diabetes - buccal insulin [ID311]

    Discontinued Reference number: GID-TAG244

    Technology appraisal guidance
    Discontinued

  12. Diabetic retinopathy - ruboxistaurin [ID382]

    Discontinued Reference number: GID-TAG386

    Technology appraisal guidance
    Discontinued

  13. Superior rectal artery embolisation for haemorrhoids

    Discontinued Reference number: GID-IPG10417

    Interventional procedures guidance
    Discontinued

  14. Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1178]

    Discontinued Reference number: GID-TA10199

    Technology appraisal guidance
    Discontinued

  15. Rituximab for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1320]

    Discontinued Reference number: GID-TA10332

    Technology appraisal guidance
    Discontinued